Garrett Vygantas
Co-founder & Managing Partner @ Riverine Ventures
San Francisco, United States
Garrett Vygantas is a Series A investor at Riverine Ventures in San Francisco focused on Health Care and Medical. Dr. Garrett Vygantas is the Founding Managing Partner at Riverine Ventures, a early stage Life Science and Healthcare focused Venture Capital firm. Previously he was a Managing Director at OSF Healthcare Ventures and served on the Investment Committee. Prior to Riverine, Garrett was Chief Business Officer at Corsair Pharma, a biotech companydeveloping innovative therapeutics to treat Pulmonary Hypertension. As an entrepreneur, Garrett co-founded TherOptix, an ocular therapeutics company and Mitre Medical, a structural heart disease medtech. He was a Partner at Jump Capital where he led the firm's healthcare investments. Prior to Jump, Garrett founded NewBridge Pharmaceuticals and served as President & CEO as EIR on the Burrill & Co Venture Capital Group. Earlier in his career, Garrett helped launch Lucentis, a breakthrough therapy for wet age related macular degeneration developed by Genentech, member of the Roche Group. Garrett previously worked with the Health Care Investment Banking group at Cowen and in Business Development at EntreMed.Garrett was a co-instructor at UCSF’s Center for BioEntrepreneurship’s “Idea to IPO” course and has advised in the formation of numerous biotech start-ups. Garrett completed his Transitional Residency at the University of Pennsylvania and holds MD & MBA degrees from Georgetown University as well as a BS in biochemistry from Boston College. He is a Kauffman Fellow.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Garrett Vygantas invests in
Stages Garrett Vygantas invests in
Countries Garrett Vygantas invests in
Investment Focus
Industry
- Health Care 8 (80%)
- Medical 4 (40%)
- Mobile 2 (20%)
- mHealth 2 (20%)
- Hospital 2 (20%)
Stage
- Series A 3 (30%)
- Series B 3 (30%)
- Series C 3 (30%)
- Corporate Round 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VIDA Intelligence
|
AI-powered clinical imaging intelligence for drug development. We make imaging a strategic asset: faster trials, stronger evidence, more confident decisions. | $2M / Series C / Apr 15, 2020 | |
AVIA
|
AVIA helps hospitals and health systems to identify, select and deploy the best emerging IT-enabled solutions to drive growth, improve operating efficiency and compete on value. We facilitate collaboration between providers and entrepreneurs to accelerate the impact and to mitigate the risk of innovation adoption. Solutions of greatest interestto our members address needs related to population health via clinical data insights, care model redesign, patient engagement and operational efficiency. | $7.2M / Series C / Aug 11, 2016 | |
Gauss Surgical
|
Gauss Surgical is a med-tech company that develops a vision-based platform for accurate and real-time measurement of surgical blood loss. They develop beautiful applications for iOS backed by sophisticated algorithms and a robust, HIPAA-compliant technical stack to enable real-time monitoring during surgery. The company was incorporated in 2011and is headquartered in Menlo Park, California. | $12.6M / Series B / Mar 30, 2016 | |
Pieces
|
Pieces is a healthcare artificial intelligence and technology company that connects health systems and the community to address clinical and social determinants of health through community networks and intelligent software and services. Our solution interprets patient information in real-time and connects health systems and community-basedorganizations to support healthier outcomes, both inside and outside of hospital walls. Using cloud-based artificial intelligence with clinically-based natural language processing (NLP) and physician-supervised machine learning, our tools help streamline clinician workflows and improve patient outcomes. Combined, our solutions, Pieces Predict and Pieces Connect, create a comprehensive and unique solution for connected community health. | $21.6M / Series A / Mar 17, 2016 | |
Visibly
|
Visibly is the first online vision test that can deliver a prescription for glasses or contacts. The test can be taken from anywhere, at any time, and a doctor issued prescription can be used to shop everywhere. Visibly is the manufacturer and distributor of Visibly Digital Acuity Product This product has not been approved by the FDA. The dataand recommendations made by the Visibly Digital Acuity Product are adjunctive (supporting) recommendations that will be used by an Eye Care Provider, along with your medical history and profile, prior corrective eyewear prescriptions, and subjective data provided about your vision. It is the responsibility of the patient to provide accurate information through the process as all of this information will be relied upon as accurate by the reviewing Eye Care Provider. | $6.5M / Series A / Feb 19, 2016 | |
|
AVIA
|
AVIA helps hospitals and health systems to identify, select and deploy the best emerging IT-enabled solutions to drive growth, improve operating efficiency and compete on value. We facilitate collaboration between providers and entrepreneurs to accelerate the impact and to mitigate the risk of innovation adoption. Solutions of greatest interestto our members address needs related to population health via clinical data insights, care model redesign, patient engagement and operational efficiency. | $6M / Series B / Sep 01, 2015 | |
Doctor On Demand
|
Doctor On Demand is a video telemedicine company, offering on-demand and scheduled visits with US-licensed healthcare providers via any smartphone, tablet, or computer. It focuses on providing solutions for employers, health plans, retail clinics, and health systems. With solutions for employers, health plans, retail clinics, and health systems,Doctor On Demand is redefining the industry with top-rated customer experience, highest clinical standards, and implementation and customer success directors, as well as 24/7 customer support.The company was founded in 2013 and is headquartered in San Francisco, California. | $62.7M / Series B / Jul 20, 2015 | |
HealthExpense, Inc.
|
HealthExpense is streamlining consumer-to-provider payments in healthcare with its pioneering, cloud-based technology/data platform. The HIPAA-certified HealthExpense platform powers market-leading track & pay, messaging, and transparency products for health plans, third party administrators and financial institutions.Consumers usecomplex, changing, and often confusing processes to pay $300+ Billion per year out-of-pocket to Healthcare Providers. Many patients are asked to take on more financial responsibility for their healthcare every year. Health plan administrators engage with consumers to manage compliant reimbursement for IRS-regulated spending every year. HealthExpense data products generate immediate cost savings, help clients differentiate themselves during this payment/reimbursement market transition, and create new data-driven visibility in payments, consumer engagement, and provider choices for administrators and patients alike.In 2014 HealthExpense’s technology was integrated with partners who serve more than 32 million consumers. Its track & pay product was launched with those partners and the number of members under management has grown dramatically since. | $6.3M / Series A / Jan 01, 2015 | |
Level Ex
|
Level Ex is a developer of professional medical video games designed for physicians to capture the challenges of practicing medicine. The company uses state-of-the-art video game technology and cognitive neuroscience to capture the challenges of practicing medicine, allowing physicians to keep up-to-speed on rare and challenging cases, new medicaldevices and drug therapies. | Corporate Round | |
MD Revolution
|
MD Revolution is a transformational digital health provider that delivers a proven high-value, affordable population health management service. As the industry leader in chronic care management (CCM) technology and service delivery, MD Revolution (MDR) is revolutionizing health by enabling value-based care within fee-for-service settings. MDRworks with physician practices, health systems, and accountable care organizations to deliver measurable improvements in the management of high-cost, high-risk chronic conditions. The software-as-a-service (SaaS) business has transformed the approach to behavior change for lifestyle diseases including diabetes, obesity, and heart disease. MDR’s RevUp CCM solution delivers statistically and clinically significant outcomes in Medicare patients. RevUp integrates with a practice’s electronic health record (EHR) to create a patient care plan and make it available securely, anytime, anywhere. Using this care plan, MD Revolution’s clinicians act as a trusted extension of the physician, engaging patients on medication compliance, nutrition, and fitness advice.By integrating health information from EHRs, digital sensors, fitness trackers, paper-based logs, and telephonic surveys, RevUp clinicians are able to provide highly relevant feedback for patients with chronic disease. A predictive intelligence engine enables real-time analysis of data, allowing physicians and clinicians to enhance clinical decision-making and deepen provider-patient interactions. | $23M / Series C |
Co-Investors
About Riverine Ventures
Riverine Ventures partners with emerging new company leaders to bring solutions to complex challenges in healthcare and the life sciences.
Riverine Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Garrett Vygantas
Co-founder & Managing Partner
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Garrett Vygantas invest in?
Garrett Vygantas invests primarily in Health Care, Medical and Mobile startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Garrett Vygantas last invest?
The most recent investment recorded for Garrett Vygantas closed in Apr 2020. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
